| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5fe74855697fef20a2e98a9b005db19 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
| filingDate |
1996-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2001-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60da697a17abcc6881849a6b232cbff5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd0023a48a7c67487402b129914bc292
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3716c8a09a8e43f851c19822609ed0c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73643faaad5f510d4f2605c79a17b333
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aea883d3f0657530c5975b99753e5de0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b100c16774544ddaf119876ceda993d |
| publicationDate |
2001-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2188907-C |
| titleOfInvention |
Combination compound for contraception based on natural estrogen |
| abstract |
The combination preparation for contraception includes from 2 to 4 first stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient, from 16 to 22 second stage daily dosage portions each including an effective amount of a combination of at least one natural estrogen and at least one natural or synthetic gestogen as active ingredient; from 2 to 4 third stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient; and from 2 to 4 final stage daily dosage portions containing a pharmaceutically acceptable placebo. The estrogen may be estradiol, an estradiol compound that is metabolized to estradiol when taken into the body, a conjugated equine estrogen or a phytoestrogen. The natural or synthetic gestogen can be natural progesterone or a synthetic gestogens, such as medroxyprogesterone acetate. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8338396-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8680084-B2 |
| priorityDate |
1995-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |